Table 3 The top 5 most sensitive tumoroid compositions for each treatment are listed with their corresponding normalized viability values
Most sensitive tumoroid cellular composition for each treatment | ||||||
|---|---|---|---|---|---|---|
Order of sensitivity | Overall drug response | Carboplatin drug response | Paclitaxel drug response | PACMA31 drug response | N773 drug response | SC144 drug response |
5 least sensitive | Composition 19 120 OVCAR3 + 400 MSC + 400 EC + 100 U937 | Composition 19 120 OVCAR3 + 400 MSC + 400 EC + 100 U937 | Composition 4 120 OVCAR3 + 20 MSC + 20 EC + 20 U937 | Composition 18 60 OVCAR3 + 300 MSC + 300 EC + 300 U937 | Composition 19 120 OVCAR3 + 400 MSC + 400 EC + 100 U937 | Composition 19 120 OVCAR3 + 400 MSC + 400 EC + 100 U937 |
4 | Composition 8 30 OVCAR3 + 150 MSC + 150 EC + 150 U937 | Composition 7 300 OVCAR3 + 60 MSC + 60 EC + 60 U937 | Composition 8 30 OVCAR3 + 150 MSC + 150 EC + 150 U937 | Composition 8 30 OVCAR3 + 150 MSC + 150 EC + 150 U937 | Composition 8 30 OVCAR3 + 150 MSC + 150 EC + 150 U937 | Composition 23 60 OVCAR3 + 500 MSC + 500 EC + 500 U937 |
3 | Composition 2 60 OVCAR3 | Composition 14 60 OVCAR3 + 400 MSC + 400 EC + 100 U937 | Composition 2 60 OVCAR3 | Composition 2 60 OVCAR3 | Composition 2 60 OVCAR3 | Composition 3 120 OVCAR3 |
2 | Composition 1 30 OVCAR3 | Composition 3 120 OVCAR3 | Composition 1 30 OVCAR3 | Composition 3 120 OVCAR3 | Composition 3 120 OVCAR3 | Composition 10 60 OVCAR3 + 500 EC |
1 most sensitive | Composition 3 120 OVCAR3 | Composition 1 30 OVCAR3 | Composition 3 120 OVCAR3 | Composition 1 30 OVCAR3 | Composition 1 30 OVCAR3 | Composition 20 60 OVCAR3 + 500 MSC + 500 EC |